News ASCO26: Lilly's Retevmo aces early-stage lung cancer trial Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.
Oncology What will ASCO 2026 reveal about oncology innovation’s new g... The next leaders in oncology will be the ones built to adapt in real time.
News Late-breakers to look out for at ASCO 2026 ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News BioMarin snaps up Alesta's lead asset for $275M BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.